Advertisment
|
|
news roundup
Parexel and Microsoft have announced a wide-ranging partnership that will initially focus on moving its Informatics technology and services onto Microsoft Azure secure cloud platform. Parexel and Microsoft aim to develop solutions to enhance patient engagement and make participation in clinical trials more accessible.
| advertisment
Tomorrow's Clinical Trial, Powered by Modern EDC
See how to cut study build time in half, eliminate migrations, and remove the need for source data verification (SDV).
 See a preview and watch the full webinar here. |
Bracket's acquisition of mProve Health broadens its capabilities in patient engagement and data collection through its mPulse ePRO platform for enabling data collection via standalone native mobile apps or SMS text. Other apps will enable communication with doctors and provide reminders and education.
| advertisment
Insight to Drive Better Partnerships
SCORR Marketing, in partnership with Applied Clinical Trials, surveyed life science professionals to gain information about the critical relationship between sponsors and service providers. Read more insights in the CRO Industry Trends report.
 Get your copy today |
| |
|
advertisment
|
|
| advertisment
ERT Video Series
Check out the ERT video series, filmed on the show floor at DIA 2017, for interviews on Innovating Clinical Trial Management, eCOA in Clinical Research: Trends and Advances, and Optimizing Clinical Trial Imaging through Advanced Technology.
 Click here to watch all 10 short videos |
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers » |
|
|
|
Advertisment
|
|
| advertisment
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient populations. In a series of white papers, PRA experts discuss the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these while engaging with the right patients.
 Read more |
A top 10 pharma has selected CRF Health's TrialMax Touch ePRO smartphone solution for its three-year global oncology trial that will involve more than 1,000 patients across 200 sites in 20 countries.
| advertisment
Navigating the Regulatory Complexities of Orphan Drugs: Know the unwritten rules of designations and what's next
Live Webinar: Thursday, November 2 at 11:00am EDT
 Register now |
Bilthoven, Netherlands based Factory CRO, a global CRO focused on medical devices and IVDs, has announced the acquisition of MileStone Research Organization. MileStone, located in San Diego, specializes in clinical research and reimbursement solutions for the medical device and biologics industries.
|
|
|
| advertisment
The Benefits of a Data-driven Approach to Feasibility
Live Webcast: Wednesday, December 6 11:00am EST
 Register now |
| advertisment
Rare Diseases and the Eye - Envisioning Strategies for Success
On Demand
 Learn more |
|
Articles
Elligo Health Research COO describes its Goes Direct™ model that supports community clinics by turning them into research by sites by provisioning personnel, processes, technology, and infrastructure to conduct clinical research.
| advertisment
Future-proofing your Pharmacovigilance Delivery Model: Achieving scalability and cost effectiveness with AI/smart machines
On Demand
 Learn more |
Often considered the same as registries, natural history studies are different in their definition and application in the overall drug development program. Natural history studies track the course of a disease over time, identifying demographic, genetic, environmental, and other variables that correlate with its development and outcomes in the absence of treatment.
|
|
|
Blog Posts
Traditional approaches to address R&D productivity are becoming less reliable, which is especially problematic in an era of pricing uncertainty.
| advertisment
RBM Technology Impact on Clinical Roles: Centralized Monitoring is streamlining activities and changing roles across clinical development
On Demand
 Learn more |
Studies designed to support regulatory approval for market release are generally the province of academic physicians who thrive on interventional, experimental trials; whereas observational, real-world studies (which can be undertaken both pre- and post-approval) require real-world physicians.
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription |
|
|
|
|
|
